Your browser doesn't support javascript.
loading
Research progress of rivaroxaban drug metabolism and gene polymorphism / 中华全科医师杂志
Article in Zh | WPRIM | ID: wpr-885378
Responsible library: WPRO
ABSTRACT
Rivaroxaban is one of the new oral anticoagulants (NOAC) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. It has clear pharmacokinetic parameters, stable plasma concentration, less drug-drug interaction and higher compliance of patients. However, the discrepancy of pharmacokinetics between individuals and drug-induced hemorrhage events frequently occur clinically, therefore the association of gene polymorphism with drug metabolism has become a research hotspot. This article reviews the research progress on pharmacokinetic characteristics of rivaroxaban and its relationship with gene polymorphism, to provide a reference for the individualized rational use of rivaroxaban.
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Journal of General Practitioners Year: 2021 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Journal of General Practitioners Year: 2021 Type: Article